generation run 2026-05-12
66 min completedmodel pipeline-v5plan not recordedrun/9c789393…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
2 further caveats recorded as free text — readable on the working page
Reproduce
- inputs
- 37 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
25 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | WebSearch/DEA/TGA | phentermine DEA schedule IV controlled substance legal status US UK Australia | 10 | 3 | Legal status verification |
| 2 | PubMed | phentermine mechanism of action pharmacology dopamine norepinephrine | 10 | 5 | Core pharmacology papers |
| 3 | ClinicalTrials.gov | phentermine obesity weight loss | 10 | 3 | Active trial landscape |
| 4 | WebSearch/Rothman 2001 | phentermine EC50 norepinephrine dopamine serotonin release | 1 | 3 | Key binding affinity data from landmark pharmacology paper |
| 5 | ClinicalTrials.gov | phentermine topiramate PHEN/TPM obesity treatment | 6 | 3 | Phentermine/topiramate pivotal trial data |
| 6 | INCHEM PIM-415 | — | 1 | 3 | WHO INCHEM is authoritative toxicology source |
| 7 | PubChem | phentermine | 1 | 1 | Primary chemical identity verification |
| 8 | WebSearch | phentermine pharmacokinetics half-life Tmax bioavailability protein binding urinary pH | 10 | 3 | PK data not available via API |
| 9 | PubMed | phentermine obesity weight loss clinical trial randomized controlled | 10 | 3 | Clinical efficacy data |
| 10 | PubMed | phentermine topiramate extended release tolerability side effects | 3 | 3 | Side effect profile data |
| 11 | WebSearch | phentermine FDA approval history 1959 Ionamin Adipex discovery synthesis | 10 | 2 | Regulatory history |
| 12 | PubMed | phentermine fenfluramine fen-phen combination heart valve pulmonary hypertension history | 1 | 1 | Historical fen-phen safety history |
| 13 | PubMed | phentermine abuse dependence addiction amphetamine stimulant | 6 | 3 | Dependence/addiction liability data |
| 14 | PubMed | phentermine cardiovascular safety hypertension pulmonary adverse effects | 5 | 3 | Cardiovascular safety data |
| 15 | WebSearch | phentermine EU withdrawal European Commission 2000 2001 market ban anorexigens | 10 | 2 | International legal status |
| 16 | WebSearch | phentermine overdose toxicity symptoms LD50 management | 10 | 2 | Toxicity and overdose safety data |
| 17 | PubMed | EQUIP CONQUER SEQUEL phentermine topiramate extended release trials | 6 | 3 | Pivotal efficacy trial data for phentermine/topiramate combination |
| 18 | PubMed | fenfluramine phentermine combination Weintraub 1992 history | 5 | 2 | Historical fen-phen clinical trial data |
| 19 | Multiple sources | Phentermine chemical identity cross-reference PubChem vs brief seed data | 3 | 1 | Data quality verification |
| 20 | PubMed | phentermine SSRI serotonin syndrome interaction | 1 | 2 | Drug interaction safety data |
| 21 | DailyMed FDA Label | — | 1 | 4 | Authoritative FDA label data for dosing and safety |
| 22 | PubMed | Connolly 1997 fenfluramine cardiac valvulopathy NEJM | 1 | 1 | Critical safety history: fenfluramine withdrawal context |
| 23 | WebSearch | phentermine SMILES CAS number 122-09-8 stereochemistry achiral | 10 | 3 | Chemical identity and stereochemistry verification |
| 24 | PubMed | Qsymia REMS teratogenicity pregnancy phentermine topiramate | 2 | 1 | Teratogenicity and pregnancy contraindication data |
| 25 | PubMed | NEJM Evidence phentermine topiramate adolescent obesity Kelly 2022 | 1 | 1 | Pediatric efficacy data |
65 claims by section — every cited sentence, checked against its source
safety17 · 12 ok
Population-level overdose data from Tennessee (2019–2022) identified phentermine in toxicology reports from fatal drug overdosessupported
Population-level study of phentermine's appearance in fatal drug overdose toxicology reports in Tennessee. j.drugpo.2023.104151
Claim in safety — inconclusiveinconclusiveworking →
Valvular disease (fen-phen combination): Histopathologically documented in both echocardiographic surveillance and autopsysupported
24 women treated with fen-phen developed valvular heart disease. Both left- and right-sided valves affected. pmid:9271479
Valvular disease (fen-phen combination): Histopathologically documented in both echocardiographic surveillance and autopsysupported
Fibroproliferative changes in pulmonary arteries and tricuspid valve. Confirms combined cardiac valvular disease and PPH can occur with fen-phen. pmid:11834685
FAERS signal analysis: An analysis of the FDA Adverse Event Report System database evaluated cardiovascular safety signals for currently marketed anti-obesity drugs including phentermine.supported
Analysis of FDA FAERS database for cardiovascular safety signals with currently marketed anti-obesity drugs. s41366-020-0544-4
Case reports associate phentermine with severe psychiatric outcomes including hypertensive crises and mental illness exacerbationssupported
Case reports of hypertension, vasoconstriction, vasculopathy, mental illness. pmid:23678625
Claim in safety — inconclusiveinconclusiveworking →
In a study of 35 patients who abruptly stopped long-term phentermine, withdrawal severity scores (modified Kampman Cocaine Selective Severity Assessment) were not significantly different from drug-naïve controls — and were strikingly different from amphetamine-dependent subjects. Cravings, the hallmark of substance dependence, were entirely absent.supported
35 patients who abruptly stopped phentermine showed no significant withdrawal symptoms compared to drug-naive controls. No cravings observed. mjt.0b013e3181d070d7
Claim in safety — inconclusiveinconclusiveworking →
A larger study investigating addiction potential of long-term phentermine treatment has been published, though full outcome data were not available for extraction in this review.supported
Investigation of whether long-term phentermine induces abuse, psychological dependence or drug craving. ijo.2013.74
A survey of 1,174 patients taking phentermine with SSRIs found zero cases of serotonin syndrome; monitored combination use is considered justifiable by bariatric medicine practitionerssupported
Survey of bariatric physicians: no cases of serotonin syndrome among 1174 patients taking phentermine + SSRIs. Monitored combination use by trained practitioners is justifiable. pmid:18777796
However, a 2025 case report documents serotonin syndrome with multi-organ injury from an anti-obesity and antidepressant drug combinationsupported
Case report of serotonin syndrome with multi-organ injury from antidepressant and antiobesity drug combination. md.0000000000041626
Claim in safety — inconclusiveinconclusiveworking →
Fenfluramine (historical): Phentermine coadministration did not significantly potentiate fenfluramine-induced serotonin depletion in mouse brain at doses far exceeding human clinical use.supported
Phentermine coadministration did not significantly alter fenfluramine-induced 5-HT depletion at doses far above human clinical doses. pmid:8793312
Claim in safety — inconclusiveinconclusiveworking →
History of drug abuse: Phentermine produces recognisable stimulant-like subjective effects in substance abusers.supported
Phentermine used as a positive control (stimulant comparator) in abuse liability study comparing atomoxetine vs methylphenidate in stimulant-preferring drug abusers. j.drugalcdep.2008.01.008
Pregnancy: The phentermine/topiramate combination (Qsymia) carries an absolute contraindication in pregnancy due to topiramate's teratogenicity, enforced through a mandatory REMS programmesupported
FDA approved phentermine-topiramate in 2012 with REMS for teratogenicity prevention. m22-1743
clinical-evidence10 · 7 ok
A 2025 randomised controlled trial evaluated phentermine 15 mg in behavioural treatment nonresponders, demonstrating clinically significant weight loss relative to placebo.supported
Phentermine 15 mg/day as adjunct to behavioral treatment in early nonresponders produced 5.9% weight loss vs 2.8% with placebo over 24 weeks (mean difference 3.1%, p=0.003, Cohen's d=0.73). s41591-025-03556-3
At the 15/92 mg dose (phentermine/topiramate), participants achieved a mean weight loss of −10.9% versus −1.6% for placebo, with 66.7% achieving ≥5% weight loss.supported
PHEN 15/TPM 92 mg: 10.9% weight loss vs 1.6% placebo. 66.7% lost ≥5% BW. oby.2011.330
A 2-year extension of CONQUER demonstrating sustained weight loss at 108 weeks: −10.5% (15/92 mg) versus −1.8% for placebo, with maintained metabolic benefits.supported
-9.3% (7.5/46 mg) and -10.5% (15/92 mg) vs -1.8% placebo. ajcn.111.024927
A 56-week randomised controlled trial of PHEN/TPM ER (15/92 mg) in adolescents aged 12–17 years demonstrated a −7.1% change in BMI versus +3.3% for placebosupported
Top-dose PHEN/TPM (15/92 mg) reduced BMI by ~7.1% vs +3.3% for placebo. evidoa2200014
Published monotherapy efficacy data indicate weight loss of approximately 5–15% of body weight over treatment courses of 12–28 weekssupported
Phentermine causes 5-15% weight loss. pmid:11471477
The LEAP trial (Long-Term Effectiveness of Anti-Obesity Medication Phentermine) is the first 24-month double-blind randomised controlled trial designed to evaluate phentermine monotherapy's long-term efficacy and cardiovascular safetysupported
Design of 24-month double-blind RCT evaluating long-term efficacy, cardiovascular risk, and safety of phentermine. First randomized trial for long-term phentermine. j.cct.2026.108219
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Pooled Phase 3 data demonstrated that PHEN/TPM ER reduced progression to type 2 diabetes, with greater benefit in patients with higher baseline cardiometabolic disease stagingsupported
Pooled EQUIP/CONQUER data showing PHEN/TPM ER efficacy for diabetes prevention correlates with cardiometabolic disease staging score. dc17-0088
Claim in clinical-evidence — inconclusiveinconclusiveworking →
comparative-pharmacology7 · 2 ok
Abrupt cessation of long-term phentermine treatment does not produce amphetamine-like withdrawal; cravings — the hallmark of substance dependence — are entirely absent in treated patients.supported
Abrupt cessation does not induce amphetamine-like withdrawal. Long-term phentermine does not induce cravings. mjt.0b013e3181d070d7
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
In vivo PET confirmation in baboons showed that phentermine at clinical doses produced no measurable striatal dopamine release, whereas amphetamine didsupported
Typical clinical doses of phentermine may not release central DA in humans (unlike amphetamine at equivalent doses). pmid:15729739
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
history6 · 4 ok
The pivotal event in phentermine's history was the publication by Weintraub and colleagues of a landmark combination study in 1992supported
34-week double-blind RCT of fen-phen (60 mg fenfluramine + 15 mg phentermine) vs placebo in 121 obese subjects. pmid:1587072
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
In August 1997, Connolly and colleagues published a report in the New England Journal of Medicine describing valvular heart disease in 24 women who had received fen-phensupported
24 women treated with fen-phen developed valvular heart disease. pmid:9271479
Autopsy evidence subsequently confirmed the pathological basis: Tomita and Zhao reported fibroproliferative plaque in pulmonary arteries from main vessels to arterioles, along with fibroproliferative tricuspid valve changes, in a patient who died of pulmonary hypertension after 7 months of fen-phen.supported
Autopsy of 36-year-old woman who died of pulmonary hypertension after 7 months of fen-phen use. Fibroproliferative changes in pulmonary arteries and tricuspid valve. pmid:11834685
The approval included a Risk Evaluation and Mitigation Strategy (REMS) programme due to topiramate's teratogenicity.supported
FDA approved phentermine-topiramate in 2012 with REMS for teratogenicity prevention. m22-1743
pharmacology6 · 2 ok
In vitro release assays using [³H]-labelled monoamine-preloaded rat brain synaptosomes established the following EC₅₀ values for phentermine-induced monoamine efflux:supported
In vitro study determining EC50 values for NE, DA, 5-HT release by amphetamine-type stimulants including phentermine. pmid:11071707
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Released norepinephrine acts on alpha-adrenergic and beta-adrenergic receptors in hypothalamic feeding circuits — including the lateral hypothalamus and paraventricular nucleus — to suppress appetite, reduce caloric intake, and potentially increase energy expenditure.supported
Phentermine releases monoamines from neuronal stores; antiobesity activity tied to NE release ability. pmid:16622292
Claim in pharmacology — inconclusiveinconclusiveworking →
summary6 · 6 ok
Dependence liability is low — abrupt cessation does not produce amphetamine-like withdrawal, and cravings are absent in long-term treated patientssupported
Abrupt cessation does not induce amphetamine-like withdrawal. Long-term phentermine does not induce cravings. mjt.0b013e3181d070d7
Its history is inseparable from the fenfluramine–phentermine ("fen-phen") crisis of 1997, when valvular heart disease linked to fenfluramine's serotonergic activity led to fenfluramine's withdrawal — phentermine itself was exonerated and remains on marketsupported
Led to voluntary market withdrawal of fenfluramine and dexfenfluramine in September 1997. pmid:9271479
As of 2026, phentermine monotherapy is the most commonly prescribed obesity medication in the US, and the LEAP trial represents the first-ever 24-month randomised controlled trial designed to evaluate its long-term efficacy and cardiovascular safety.supported
Design of 24-month double-blind RCT evaluating long-term efficacy, cardiovascular risk, and safety of phentermine in adults with overweight/obesity. First randomized trial for long-term phentermine (approval predates such requirements). j.cct.2026.108219
Phentermine acts primarily as a norepinephrine releasing agent (NET EC₅₀ = 39.4 nM), with substantially weaker dopamine (DAT EC₅₀ = 262 nM) and minimal serotonin release (SERT EC₅₀ = 3,511 nM)supported
Phentermine EC50: NE 39.4 nM, DA 262 nM, 5-HT 3511 nM. pmid:11071707
PET imaging in nonhuman primates confirms that clinical doses do not produce measurable striatal dopamine release, distinguishing phentermine from amphetamine at the neurochemical levelsupported
Typical clinical doses of phentermine may not release central DA in humans (unlike amphetamine at equivalent doses). pmid:15729739
A case report documents pulmonary hypertension after just 5 weeks of monotherapysupported
Case of 29-year-old woman developing pulmonary hypertension after 5 weeks of phentermine monotherapy. ymj.2010.51.6.
neuroscience4 · 3 ok
PET imaging in baboons demonstrated that phentermine at doses equivalent to clinical use does not displace [¹¹C]raclopride in the striatum, indicating negligible synaptic dopamine release, whereas amphetamine at equivalent doses produces robust displacementsupported
Typical clinical doses of phentermine may not release central DA in humans (unlike amphetamine at equivalent doses). pmid:15729739
However, neurophysiological recordings in rat nucleus accumbens shell reveal that phentermine does modulate NAc activity: it produces inhibitory imbalance in spiking activity and alters beta, theta, and delta local field potential oscillationssupported
Effects in NAc shell depend on D1/D2 receptor activation. Beta, theta, delta oscillation modulation documented. jn.00012.2015
Claim in neuroscience — inconclusiveinconclusiveworking →
In freely moving rats, microdialysis measurements show that phentermine increases both striatal dopamine and serotonin release in a dose-dependent mannersupported
In vivo microdialysis study measuring phentermine effects on striatal DA and 5-HT release in freely moving rats. pmid:9578237
chemistry3 · 2 ok
Two pharmaceutical forms have been marketed: (1) the hydrochloride salt (Adipex-P 37.5 mg tablets/capsules; Lomaira 8 mg tablets), which is rapidly absorbed, and (2) a phentermine ion-exchange resin formulation (Ionamin, now discontinued in the US), which provides a considerably slower absorption profilesupported
HCl salt readily soluble; resinate absorption slower. pmid:23678625
Claim in chemistry — inconclusiveinconclusiveworking →
All identifiers verified against PubChem CID 4771.supported
CID 4771: Molecular formula C10H15N, MW 149.23, IUPAC 2-methyl-1-phenylpropan-2-amine, InChIKey DHHVAGZRUROJKS-UHFFFAOYSA-N pmid:4771
receptor-pharmacology3 · 3 ok
The Rothman et al. (2001) functional release assay remains the definitive dataset:supported
In vitro study determining EC50 values for NE, DA, 5-HT release by amphetamine-type stimulants including phentermine. pmid:11071707
A PET study in anaesthetised baboons directly addressed whether phentermine releases central dopamine at clinically relevant dosessupported
PET study in baboons showing... Typical clinical doses of phentermine may not release central DA in humans (unlike amphetamine at equivalent doses). pmid:15729739
In freely moving rats, phentermine increased both striatal dopamine and serotonin release in a dose-dependent manner at pharmacological doses, as measured by in vivo microdialysissupported
In vivo microdialysis study measuring phentermine effects on striatal DA and 5-HT release in freely moving rats. pmid:9578237
pharmacokinetic-detail2 · 0 ok
legal-status1 · 0 ok
Claim in legal-status — inconclusiveinconclusiveworking →